STAT

Opinion: I thought patriarchy in science was fading. Then I saw it in the data

Ending gender inequity and patriarchy in science will require more than playing the waiting game. I intend to wait no longer and will use data — and connections — to…

As I returned home from this year’s Women in Statistics and Data Science Conference, one word rang loudly in my ears: patriarchy.

In a presentation on the impact of gender on women’s careers, Carnegie Mellon statistician Dalene Stangl boldly claimed that although the term may be out of favor, patriarchy is “alive and well” and that “it happened to me.”

At first, there was little I recognized in Stangl’s story. The term “patriarchy” is loaded with the history of gender oppression that, thanks to the determination of women like Stangl who came before me, seemed worlds apart from my own experience. I’ve had many male supporters

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks